Zhongwen Qi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhongwen Qi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Junping Zhang
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine, Tianjin, China
6 shared publications Zhipeng Yan
Medical Experiment Center First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin China
5 shared publicationsTingting Li
Department of Cardiovascular, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
3 shared publicationsAolin Li
Department of Cardiovascular, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
2 shared publications- Fengqin Xu
Department of Cardiovascular Disease, Beijing Xiyuan Hospital, China Academy of Chinese Medical Sciences, China
2 shared publications Ke Zhu
Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, P.R. China
2 shared publications
Latest Publications
- Open Access
- 23 February 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1602893
Integrative multi-omics profiling of mild cognitive impairment in older patients combined with coronary heart disease: a cross-sectional cohort study
Introduction: With the escalating global burden of population ageing, the comorbidity of geriatric coronary heart disease (CHD) and mild cognitive impairment (MCI) has emerged as a significant public health concern. This study aims to elucidate the underlying clinical disease features of MCI in elderly CHD patients through comprehensive multi-omics analyses and to establish a detailed phenomics profile. Methods: A cross-sectional study design will be implemented, enrolling 364 elderly patients diagnosed with CHD. Participants will be divided into MCI and cognitively normal groups based on Montreal Cognitive Assessment (MoCA) scores. Extensive data collection will include demographic characteristics, clinical parameters, laboratory investigations, and echocardiographic findings. These clinical data will be integrated with multi-omics analyses (including genomics, proteomics, and metabolomics) to identify differential biomarkers between the two groups. Discussion: This study anticipates constructing an integrative network map delineating the multi-omics mechanisms underlying MCI in elderly CHD patients by correlating macroscopic clinical phenotypes with microscopic molecular characteristics. The findings are expected to provide a scientific foundation for early detection and intervention strategies. While acknowledging the inherent limitations of the cross-sectional design, future prospective studies are warranted to validate these findings. This investigation offers novel insights and potential therapeutic strategies for the prevention and management of comorbid CHD and MCI in the ageing population. This study has completed registration in the International Traditional Medicine Clinical Trial Registration Platform (ITMCTR2024000871). Clinical Trial Registration: https://itmctr.ccebtcm.org.cn , identifier ITMCTR2024000871.
- 23 February 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1602893
Open AccessIntegrative multi-omics profiling of mild cognitive impairment in older patients combined with coronary heart disease: a cross-sectional cohort study
Introduction: With the escalating global burden of population ageing, the comorbidity of geriatric coronary heart disease (CHD) and mild cognitive impairment (MCI) has emerged as a significant public health concern. This study aims to elucidate the underlying clinical disease features of MCI in elderly CHD patients through comprehensive multi-omics analyses and to establish a detailed phenomics profile. Methods: A cross-sectional study design will be implemented, enrolling 364 elderly patients diagnosed with CHD. Participants will be divided into MCI and cognitively normal groups based on Montreal Cognitive Assessment (MoCA) scores. Extensive data collection will include demographic characteristics, clinical parameters, laboratory investigations, and echocardiographic findings. These clinical data will be integrated with multi-omics analyses (including genomics, proteomics, and metabolomics) to identify differential biomarkers between the two groups. Discussion: This study anticipates constructing an integrative network map delineating the multi-omics mechanisms underlying MCI in elderly CHD patients by correlating macroscopic clinical phenotypes with microscopic molecular characteristics. The findings are expected to provide a scientific foundation for early detection and intervention strategies. While acknowledging the inherent limitations of the cross-sectional design, future prospective studies are warranted to validate these findings. This investigation offers novel insights and potential therapeutic strategies for the prevention and management of comorbid CHD and MCI in the ageing population. This study has completed registration in the International Traditional Medicine Clinical Trial Registration Platform (ITMCTR2024000871). Clinical Trial Registration: https://itmctr.ccebtcm.org.cn , identifier ITMCTR2024000871.
- Open Access
- 1 March 2025
- Published by Wiley in Obesity Reviews
- Vol. 26 (7) , e13912
Role of epicardial adipose tissue in heart failure with preserved ejection fraction: An emerging molecular mechanism and therapeutic potential
Summary: With the evolving landscape of diseases, heart failure with preserved ejection fraction (HFpEF) now encompasses more than half of all heart failure patients. This condition is clinically diverse, involving multiple organ systems and often occurring alongside the aging process. To deeply investigate the common pathogenesis of HFpEF and to explore new therapeutic approaches is of great significance for the treatment of HFpEF. Epicardial adipose tissue (EAT) is not only a dynamic organ with biological functions but also physically adjacent to the myocardium and coronary arteries, endowing it with unique properties as a visceral fat depot. During pathology, EAT can secrete adipocytokines via paracrine mechanisms, establishing direct communication with the heart and vascular, thereby impacting cardiac function. This review aims to elucidate the intricate relationship between EAT and cardiac function in HFpEF, delineate the roles of adipocytes, macrophages, lymphocytes, and stem cells within EAT in HFpEF, and summarize the progress in research regarding drug therapies targeting EAT for HFpEF treatment.
- 1 March 2025
- Published by Wiley in Obesity Reviews
- Vol. 26 (7) , e13912
Open AccessRole of epicardial adipose tissue in heart failure with preserved ejection fraction: An emerging molecular mechanism and therapeutic potential
Summary: With the evolving landscape of diseases, heart failure with preserved ejection fraction (HFpEF) now encompasses more than half of all heart failure patients. This condition is clinically diverse, involving multiple organ systems and often occurring alongside the aging process. To deeply investigate the common pathogenesis of HFpEF and to explore new therapeutic approaches is of great significance for the treatment of HFpEF. Epicardial adipose tissue (EAT) is not only a dynamic organ with biological functions but also physically adjacent to the myocardium and coronary arteries, endowing it with unique properties as a visceral fat depot. During pathology, EAT can secrete adipocytokines via paracrine mechanisms, establishing direct communication with the heart and vascular, thereby impacting cardiac function. This review aims to elucidate the intricate relationship between EAT and cardiac function in HFpEF, delineate the roles of adipocytes, macrophages, lymphocytes, and stem cells within EAT in HFpEF, and summarize the progress in research regarding drug therapies targeting EAT for HFpEF treatment.
- Open Access
- 31 January 2024
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 48 (1) , 19-36
Primordial Drivers of Diabetes Heart Disease: Comprehensive Insights into Insulin Resistance
Insulin resistance has been regarded as a hallmark of diabetes heart disease (DHD). Numerous studies have shown that insulin resistance can affect blood circulation and myocardium, which indirectly cause cardiac hypertrophy and ventricular remodeling, participating in the pathogenesis of DHD. Meanwhile, hyperinsulinemia, hyperglycemia, and hyperlipidemia associated with insulin resistance can directly impair the metabolism and function of the heart. Targeting insulin resistance is a potential therapeutic strategy for the prevention of DHD. Currently, the role of insulin resistance in the pathogenic development of DHD is still under active research, as the pathological roles involved are complex and not yet fully understood, and the related therapeutic approaches are not well developed. In this review, we describe insulin resistance and add recent advances in the major pathological and physiological changes and underlying mechanisms by which insulin resistance leads to myocardial remodeling and dysfunction in the diabetic heart, including exosomal dysfunction, ferroptosis, and epigenetic factors. In addition, we discuss potential therapeutic approaches to improve insulin resistance and accelerate the development of cardiovascular protection drugs.
- 31 January 2024
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 48 (1) , 19-36
Open AccessPrimordial Drivers of Diabetes Heart Disease: Comprehensive Insights into Insulin Resistance
Insulin resistance has been regarded as a hallmark of diabetes heart disease (DHD). Numerous studies have shown that insulin resistance can affect blood circulation and myocardium, which indirectly cause cardiac hypertrophy and ventricular remodeling, participating in the pathogenesis of DHD. Meanwhile, hyperinsulinemia, hyperglycemia, and hyperlipidemia associated with insulin resistance can directly impair the metabolism and function of the heart. Targeting insulin resistance is a potential therapeutic strategy for the prevention of DHD. Currently, the role of insulin resistance in the pathogenic development of DHD is still under active research, as the pathological roles involved are complex and not yet fully understood, and the related therapeutic approaches are not well developed. In this review, we describe insulin resistance and add recent advances in the major pathological and physiological changes and underlying mechanisms by which insulin resistance leads to myocardial remodeling and dysfunction in the diabetic heart, including exosomal dysfunction, ferroptosis, and epigenetic factors. In addition, we discuss potential therapeutic approaches to improve insulin resistance and accelerate the development of cardiovascular protection drugs.
- Open Access
- 31 August 2023
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 61 (1) , 1364-1373
Novel treatment from a botanical formulation Si-Miao-Yong-an decoction inhibits vasa vasorum angiogenesis and stabilizes atherosclerosis plaques via the Wnt1/β-catenin signalling pathway
Si-Miao-Yong-An (SMYA) has been widely used for the clinical treatment of atherosclerosis (AS). Yet, its complete mechanism of action is not fully understood. To investigate the mechanism by which SMYA stabilizes AS plaques from the perspective of inhibiting vasa vasorum (VV) angiogenesis. We used male ApoE-/- mice to establish an AS model. The mice were divided into model, SMYA (11.7 mg/kg/d), and simvastatin (SVTT) (2.6 mg/kg/d) groups. Mice were given SMYA or SVTT by daily gavage for 8 weeks. HE staining, immunofluorescence double-labelling staining, and immunohistochemical staining were used to observe the pathological changes in the plaques. Finally, the protein and mRNA expression levels of the Wnt1/β-catenin signalling pathway were detected by Western blot and qRT-PCR, respectively. SMYA significantly attenuated cholesterol crystallization, and lipid accumulation in AS plaques, resulting in smaller plaque size (0.25 mm2 vs. 0.46 mm2), and lowering ratio of plaque to lumen area (20.04% vs. 38.33%) and VV density (50.64/mm2 vs. 98.02/mm2). Meanwhile, SMYA suppressed both the positive area percentage of Wnt1 (2.53 vs. 3.56), β-catenin (3.33 vs. 5.65) and Cyclin D1 (2.10 vs. 3.27) proteins in the aortic root plaques, and mRNA expression of Wnt1 (1.38 vs. 2.09), β-catenin (2.05 vs. 3.25) and Cyclin D1 (1.39 vs. 2.57). SMYA has a protective effect against AS, which may be related to its anti-VV angiogenesis in plaques, suggesting that SMYA has the potential as a novel botanical formulation in the treatment of AS.
- 31 August 2023
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 61 (1) , 1364-1373
Open AccessNovel treatment from a botanical formulation Si-Miao-Yong-an decoction inhibits vasa vasorum angiogenesis and stabilizes atherosclerosis plaques via the Wnt1/β-catenin signalling pathway
Si-Miao-Yong-An (SMYA) has been widely used for the clinical treatment of atherosclerosis (AS). Yet, its complete mechanism of action is not fully understood. To investigate the mechanism by which SMYA stabilizes AS plaques from the perspective of inhibiting vasa vasorum (VV) angiogenesis. We used male ApoE-/- mice to establish an AS model. The mice were divided into model, SMYA (11.7 mg/kg/d), and simvastatin (SVTT) (2.6 mg/kg/d) groups. Mice were given SMYA or SVTT by daily gavage for 8 weeks. HE staining, immunofluorescence double-labelling staining, and immunohistochemical staining were used to observe the pathological changes in the plaques. Finally, the protein and mRNA expression levels of the Wnt1/β-catenin signalling pathway were detected by Western blot and qRT-PCR, respectively. SMYA significantly attenuated cholesterol crystallization, and lipid accumulation in AS plaques, resulting in smaller plaque size (0.25 mm2 vs. 0.46 mm2), and lowering ratio of plaque to lumen area (20.04% vs. 38.33%) and VV density (50.64/mm2 vs. 98.02/mm2). Meanwhile, SMYA suppressed both the positive area percentage of Wnt1 (2.53 vs. 3.56), β-catenin (3.33 vs. 5.65) and Cyclin D1 (2.10 vs. 3.27) proteins in the aortic root plaques, and mRNA expression of Wnt1 (1.38 vs. 2.09), β-catenin (2.05 vs. 3.25) and Cyclin D1 (1.39 vs. 2.57). SMYA has a protective effect against AS, which may be related to its anti-VV angiogenesis in plaques, suggesting that SMYA has the potential as a novel botanical formulation in the treatment of AS.
- Open Access
- 9 January 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 1077290
Cardiac repair after myocardial infarction: A two-sided role of inflammation-mediated
Myocardial infarction is the leading cause of death and disability worldwide, and the development of new treatments can help reduce the size of myocardial infarction and prevent adverse cardiovascular events. Cardiac repair after myocardial infarction can effectively remove necrotic tissue, induce neovascularization, and ultimately replace granulation tissue. Cardiac inflammation is the primary determinant of whether beneficial cardiac repair occurs after myocardial infarction. Immune cells mediate inflammatory responses and play a dual role in injury and protection during cardiac repair. After myocardial infarction, genetic ablation or blocking of anti-inflammatory pathways is often harmful. However, enhancing endogenous anti-inflammatory pathways or blocking endogenous pro-inflammatory pathways may improve cardiac repair after myocardial infarction. A deficiency of neutrophils or monocytes does not improve overall cardiac function after myocardial infarction but worsens it and aggravates cardiac fibrosis. Several factors are critical in regulating inflammatory genes and immune cells’ phenotypes, including DNA methylation, histone modifications, and non-coding RNAs. Therefore, strict control and timely suppression of the inflammatory response, finding a balance between inflammatory cells, preventing excessive tissue degradation, and avoiding infarct expansion can effectively reduce the occurrence of adverse cardiovascular events after myocardial infarction. This article reviews the involvement of neutrophils, monocytes, macrophages, and regulatory T cells in cardiac repair after myocardial infarction. After myocardial infarction, neutrophils are the first to be recruited to the damaged site to engulf necrotic cell debris and secrete chemokines that enhance monocyte recruitment. Monocytes then infiltrate the infarct site and differentiate into macrophages and they release proteases and cytokines that are harmful to surviving myocardial cells in the pre-infarct period. As time progresses, apoptotic neutrophils are cleared, the recruitment of anti-inflammatory monocyte subsets, the polarization of macrophages toward the repair phenotype, and infiltration of regulatory T cells, which secrete anti-inflammatory factors that stimulate angiogenesis and granulation tissue formation for cardiac repair. We also explored how epigenetic modifications regulate the phenotype of inflammatory genes and immune cells to promote cardiac repair after myocardial infarction. This paper also elucidates the roles of alarmin S100A8/A9, secreted frizzled-related protein 1, and podoplanin in the inflammatory response and cardiac repair after myocardial infarction.
- 9 January 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 1077290
Open AccessCardiac repair after myocardial infarction: A two-sided role of inflammation-mediated
Myocardial infarction is the leading cause of death and disability worldwide, and the development of new treatments can help reduce the size of myocardial infarction and prevent adverse cardiovascular events. Cardiac repair after myocardial infarction can effectively remove necrotic tissue, induce neovascularization, and ultimately replace granulation tissue. Cardiac inflammation is the primary determinant of whether beneficial cardiac repair occurs after myocardial infarction. Immune cells mediate inflammatory responses and play a dual role in injury and protection during cardiac repair. After myocardial infarction, genetic ablation or blocking of anti-inflammatory pathways is often harmful. However, enhancing endogenous anti-inflammatory pathways or blocking endogenous pro-inflammatory pathways may improve cardiac repair after myocardial infarction. A deficiency of neutrophils or monocytes does not improve overall cardiac function after myocardial infarction but worsens it and aggravates cardiac fibrosis. Several factors are critical in regulating inflammatory genes and immune cells’ phenotypes, including DNA methylation, histone modifications, and non-coding RNAs. Therefore, strict control and timely suppression of the inflammatory response, finding a balance between inflammatory cells, preventing excessive tissue degradation, and avoiding infarct expansion can effectively reduce the occurrence of adverse cardiovascular events after myocardial infarction. This article reviews the involvement of neutrophils, monocytes, macrophages, and regulatory T cells in cardiac repair after myocardial infarction. After myocardial infarction, neutrophils are the first to be recruited to the damaged site to engulf necrotic cell debris and secrete chemokines that enhance monocyte recruitment. Monocytes then infiltrate the infarct site and differentiate into macrophages and they release proteases and cytokines that are harmful to surviving myocardial cells in the pre-infarct period. As time progresses, apoptotic neutrophils are cleared, the recruitment of anti-inflammatory monocyte subsets, the polarization of macrophages toward the repair phenotype, and infiltration of regulatory T cells, which secrete anti-inflammatory factors that stimulate angiogenesis and granulation tissue formation for cardiac repair. We also explored how epigenetic modifications regulate the phenotype of inflammatory genes and immune cells to promote cardiac repair after myocardial infarction. This paper also elucidates the roles of alarmin S100A8/A9, secreted frizzled-related protein 1, and podoplanin in the inflammatory response and cardiac repair after myocardial infarction.
- Open Access
- 1 June 2021
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 14, 2647-2666
Pyroptosis: A New Regulating Mechanism in Cardiovascular Disease
Pyroptosis is a kind of pro-inflammatory cell death. Compared with autophagy and apoptosis, pyroptosis has unique characteristics in morphology and mechanism. Specifically, pyroptosis is a kind of cell lysis mediated by the Gasdermin family, releases inflammatory cytokines IL-1β and IL-18. There are three different forms of mechanism, which are caspase-1-mediated, caspase-4/5/11-mediated and caspase-3-mediated. A large number of studies have proved that pyroptosis is closely related to cardiovascular disease. This paper reviewed the recent progress in the related research on pyroptosis and myocardial infarction, ischemia-reperfusion, atherosclerosis, diabetic cardiomyopathy, arrhythmia, heart failure hypertension and Kawasaki disease. Therefore, we believe that pyroptosis may be a new therapeutic target in the cardiovascular field.
- 1 June 2021
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 14, 2647-2666
Open AccessPyroptosis: A New Regulating Mechanism in Cardiovascular Disease
Pyroptosis is a kind of pro-inflammatory cell death. Compared with autophagy and apoptosis, pyroptosis has unique characteristics in morphology and mechanism. Specifically, pyroptosis is a kind of cell lysis mediated by the Gasdermin family, releases inflammatory cytokines IL-1β and IL-18. There are three different forms of mechanism, which are caspase-1-mediated, caspase-4/5/11-mediated and caspase-3-mediated. A large number of studies have proved that pyroptosis is closely related to cardiovascular disease. This paper reviewed the recent progress in the related research on pyroptosis and myocardial infarction, ischemia-reperfusion, atherosclerosis, diabetic cardiomyopathy, arrhythmia, heart failure hypertension and Kawasaki disease. Therefore, we believe that pyroptosis may be a new therapeutic target in the cardiovascular field.
- Open Access
- 10 February 2021
- Published by Springer Nature in Research Square
Mesenchymal Stem Cell Immunomodulation: A Novel Intervention Mechanism in Cardiovascular Disease
Mesenchymal stem cells (MSCs) belong to the family of pluripotent stem cells, which have an obvious multi-directional differentiation potential and can regulate the immune response of the organism by influencing immune cell subsets, thus they have excellent prospects for application in inflammation, immune diseases, and organ transplantation. Numerous studies have shown that MSCs are a promising strategy for the treatment of cardiovascular disease by modulating immune cell subsets and coordinating local and systemic innate and adaptive immune responses, thereby enabling the formation of a stable inflammatory microenvironment in damaged cardiac tissues. In this review, we summarize the mechanisms by which MSCs interact with immune cells and exert immunomodulatory effects, and explain the therapeutic effects of this mechanism in the treatment of cardiovascular diseases. A feasibility analysis is provided for the application of MSCs in cardiovascular diseases.
- 10 February 2021
- Published by Springer Nature in Research Square
Open AccessMesenchymal Stem Cell Immunomodulation: A Novel Intervention Mechanism in Cardiovascular Disease
Mesenchymal stem cells (MSCs) belong to the family of pluripotent stem cells, which have an obvious multi-directional differentiation potential and can regulate the immune response of the organism by influencing immune cell subsets, thus they have excellent prospects for application in inflammation, immune diseases, and organ transplantation. Numerous studies have shown that MSCs are a promising strategy for the treatment of cardiovascular disease by modulating immune cell subsets and coordinating local and systemic innate and adaptive immune responses, thereby enabling the formation of a stable inflammatory microenvironment in damaged cardiac tissues. In this review, we summarize the mechanisms by which MSCs interact with immune cells and exert immunomodulatory effects, and explain the therapeutic effects of this mechanism in the treatment of cardiovascular diseases. A feasibility analysis is provided for the application of MSCs in cardiovascular diseases.
- Open Access
- 1 June 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 114, 108785
Si-Miao-Yong-An on promoting the maturation of Vasa Vasorum and stabilizing atherosclerotic plaque in ApoE-/- mice: An experimental study
- 1 June 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 114, 108785
Open AccessSi-Miao-Yong-An on promoting the maturation of Vasa Vasorum and stabilizing atherosclerotic plaque in ApoE-/- mice: An experimental study